Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis
Background & Aims
The influence of osteoporosis and liver disease on fracture risk is not well characterized in patients with primary biliary cirrhosis (PBC). We studied a large series of women with PBC to assess the prevalence and risk factors for fractures and the fracture threshold.
Methods
In female patients with PBC (n = 185; age, 55.7 ± 0.7 years; range 28–79 years), age, duration of PBC, menopausal status, and histologic stage and severity of liver disease were assessed. Vertebral and non-vertebral fractures were recorded in 170 and 172 patients, respectively. Osteoporosis and osteopenia were diagnosed based on densitometry analysis.
Results
The prevalences of vertebral, non-vertebral, and overall fractures were 11.2%, 12.2%, 20.8%, respectively. Osteoporosis was significantly more frequent in patients with PBC than in normal women. Osteoporosis was associated with age, weight, height, histologic stage, severity, and duration of liver damage; fractures were associated with osteoporosis, menopause, age, and height but not with severity of PBC. Osteoporosis was a risk factor for vertebral fracture (odds ratio [OR], 8.48; 95% confidence interval [CI]: 2.67–26.95). Lumbar T score <–1.5 (OR, 8.27; 95% CI: 1.84–37.08) and femoral neck T score <–1.5 (OR, 6.83; 95% CI: 1.48–31.63) were significant risk factors for vertebral fractures.
Conclusions
Fractures, particularly vertebral fractures, are associated with osteoporosis, osteopenia, and T scores less than –1.5, whereas osteoporosis and osteopenia are associated with the severity of liver damage. Patients with T scores less than –1.5 might require additional monitoring and be considered for therapy to prevent fractures.
Keywords: Metabolic Bone Disease, Bone Mineral Density, Osteoporosis, Osteopenia
Abbreviations used in this paper: PBC, primary biliary cirrhosis, BMD, bone mineral density
To access this article, please choose from the options below
Conflicts of interest The authors disclose no conflicts.
Funding Supported, in part, by Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, and FIS-08/0105, Ministerio de Ciencia e Innovación, Spain.
PII: S0016-5085(10)00207-6
doi:10.1053/j.gastro.2010.02.016
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

